Biosimilar Bevacizumab: Why are "Real-World Evidence" Studies Ending the Debate on Biosimilar Quality?
For years, some skeptics questioned if a "highly similar" drug could truly match the performance of the original—but in 2026, "Real-World Evidence" (RWE) has officially settled the score. Massive data sets from millions of patient-months of biosimilar bevacizumab use have confirmed that there are no clinically meaningful differences in safety, purity, or potency compared to the reference...
0 Comments 0 Shares 94 Views 0 Reviews